NCT02626481 2026-04-07
IFM2014-04
University Hospital, Lille
Phase 2 Completed
Clinical Trials
24 trialsNCT05807048 2026-03-10
Daratumumab in STK11 Mutated NSCLC
NYU Langone Health
Phase 2 Completed
NCT03477539 2026-03-09
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT06549634 2026-02-27
Biomarkers of AKI in Patients Receiving Daratumumab
Brigham and Women's Hospital
Completed
NCT01665794 2025-12-22
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Chicago
Phase 1/2 Completed
NCT05511428 2025-11-21
Home Based Daratumumab Administration for Patients With Multiple Myeloma
Thomas Jefferson University
Phase 4 Completed
NCT01415882 2025-09-05
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Phase 2 Completed
NCT05835726 2025-08-15
DILEMMA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Completed
NCT03012880 2025-06-04
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03490344 2025-05-25
Short Course Daratumumab in Patients With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03473730 2025-01-30
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT04714372 2024-10-24
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT03177460 2024-05-03
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT05306587 2024-04-03
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
Odense University Hospital
Completed
NCT03450057 2024-03-29
DARE
Hellenic Society of Hematology
Phase 2 Completed
NCT03311828 2024-03-12
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT03224507 2023-11-24
MASTER
University of Alabama at Birmingham
Phase 2 Completed
NCT03215524 2023-08-04
DCDP
Canadian Myeloma Research Group
Phase 2 Completed
NCT03187262 2022-11-23
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02977494 2022-05-31
GMMG-DANTE
UniversitÀtsklinikum Hamburg-Eppendorf
Phase 2 Completed
NCT03697629 2022-02-15
A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma
Canadian Myeloma Research Group
Phase 2 Completed
NCT02841033 2021-05-07
Daratumumab for the Treatment of Patients With AL Amyloidosis
Boston Medical Center
Phase 1/2 Completed
NCT02944565 2019-09-09
Daratumumab in Treating Patients With Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02419118 2017-11-07
DARA
Vejle Hospital
Phase 2/3 Completed